Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)

NCT00128713 is registered in ClinicalTrials.gov with Carelon Research as lead sponsor.

NCT NCT00128713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Lead sponsor
Carelon Research
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
January 31, 2008
Enrollment
1,351 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenia